SMTINasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Sanara MedTech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$33.14−0.02 (-0.06%)
Close on Oct 19, 2026
- Market cap
- $287.08M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
92.7%+3.1 pts over 5 years
Operating margin
7.1%+39.4 pts over 5 years
Net margin
-36.4%−7.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.0% | +31.0% | +45.9% | +40.8% | |
| Gross profit | +21.7% | +34.3% | +46.9% | +44.1% | |
| Operating income | +480.3% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 49.1% | -70.9% | -165.7% | |
| Return on assets | -23.3% | -42.4% | -46.7% | |
| Current ratio | 1.43 | 1.27 | 1.80 | |
| Debt to equity | – | – | 7.74 | |
| Net debt to EBITDA | – | – | 2.61× | |
| Interest coverage | -1.6× | -436.7× | 1.1× | |
| Inventory turnover | 2.5× | 1.7× | 2.2× | |
| Capex to revenue | 0.1% | 3.5% | 4.5% | |
| Diluted shares | 1M | 6M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sanara MedTech generated $20.43M from operations and spent $5.42M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$20.43M
Used
$5.42M
Capital expenditure$5.42M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-36.4%
×Asset turnover1.28×
×Equity multiplier3.55×
=Return on equity, FY2025-165.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -36.4% | 1.28× | 3.55× | -165.7% |
| FY2024 | -11.2% | 1.07× | 1.92× | -22.9% |
| FY2023 | -6.6% | 0.96× | 1.56× | -9.9% |
| FY2022 | -17.3% | 0.94× | 1.34× | -21.9% |
| FY2021 | -32.8% | 1.04× | 1.26× | -43.1% |
| FY2020 | -28.5% | 1.49× | 1.67× | -70.9% |
| FY2019 | -23.9% | 1.83× | 1.84× | -80.6% |
| FY2018 | -10.3% | 2.97× | 5.70× | -174.2% |
| FY2017 | 5.3% | 2.87× | -13.69× | -206.7% |
| FY2016 | -7.5% | 3.09× | -2.10× | 49.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$37.56M
- Cash generatingOperating cash flow above zero$6.79M
- Return on assets improvedROA up on the prior year-13.1% → -42.6%
- Earnings backed by cashOperating cash flow above net income$6.79M vs -$37.56M
- Less leverageLong-term debt to assets fell34.8% → 63.0%
- Better liquidityCurrent ratio rose2.18 → 1.80
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year90.61% → 92.71%
- More efficientAsset turnover rose1.17 → 1.17